Evaxion Biotech Incorporates Filings into Registration Statements

TL;DR

EVX is rolling over old filings into new ones, standard procedure for ongoing stock activity.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on March 26, 2025, to incorporate by reference its previous filings into various registration statements. These include S-8 (File No. 333-255064), F-3 (File No. 333-265132), and multiple F-1 and F-3 filings, indicating ongoing capital raising or securities offerings.

Why It Matters

This filing is procedural, indicating the company is maintaining active registration statements, which is often a prerequisite for future stock offerings or employee stock plans.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not introduce new financial or operational risks.

Key Players & Entities

• Evaxion Biotech A/S (company) — Registrant
• 333-255064 (registration_statement) — Form S-8 File Number
• 333-265132 (registration_statement) — Form F-3 File Number
• 333-266050 (registration_statement) — Form F-1 File Number
• 333-276505 (registration_statement) — Form F-1 File Number
• 333-279153 (registration_statement) — Form F-1 File Number
• 333-283304 (registration_statement) — Form F-1 File Number
• 333-285778 (registration_statement) — Form F-3 File Number

FAQ

From the Filing

0001104659-25-028259.txt : 20250326 0001104659-25-028259.hdr.sgml : 20250326 20250326163023 ACCESSION NUMBER: 0001104659-25-028259 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250326 FILED AS OF DATE: 20250326 DATE AS OF CHANGE: 20250326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25773686 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 tm258932d5_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s (the “Company”) registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. As previously disclosed, (i) on October 3, 2022, the Company entered into a Capital on Demand TM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“Jones”), pursuant to which the Company may sell from time to time, at its option, American Depositary Shares (“ADSs”), each representing fifty (50) ordinary share, DKK 0.25 nominal value per share, of the Company (the “Ordinary Shares”), through or to Jones, as sales agent or principal, and (ii) the Company filed a prospectus supplement with the Securities and Exchange Commission (the “SEC”) on October 3, 2022 relating to the offer and sale of up to $14,439,000 of ADSs pursuant to the Sales Agreement (the “Prior ATM Program”). On March 26, 2025, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s registration statement on Form F-3 (File No. 333-285778) for the issuance and sale, if any, of up to an additional $4,480,000 of ADSs pursuant to the Sales Agreement. The Company will not make further sales under the Prior ATM Program. The Company is not obligated to make any sales of ADSs under the Sales Agreement, and the Company cannot provide any assurances that it will issue any ADSs pursuant to the Sales Agreement. The offering of ADSs pursuant to the Sales Agreement will terminate as permitted therein. The Company is obligated to pay Jones an aggregate sales agent commission equal to 3.0% of the gross sales price for ADSs sold under the Sales Agreement. The Company has also provided Jones with customary indemnification rights and expense reimbursements. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as Exhibit 4.7 to the